Fenofibrate exhibits a high potential to suppress the formation of squamous cell carcinoma in an oral-specific 4-nitroquinoline 1-oxide/arecoline mouse model

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 4, 2011, Pages 558-564

  Chang, Nai Wen ^a   Tsai, Ming Hsui ^b   Lin, Chingju ^a   Hsu, Hui Ting ^c   Chu, Pei Yi ^c   Yeh, Chung Min ^c   Chiu, Chang Fang ^b   Yeh, Kun Tu ^c,d  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

4 Nitroquinoline 1 oxide; Arecoline; Fenofibrate; Oral squamous cell carcinoma

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; ACETYL COENZYME A CARBOXYLASE; ARECOLINE; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; FATTY ACID SYNTHASE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER SIZE; CARCINOGENESIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIPID BLOOD LEVEL; MALE; MOUSE; MOUTH CANCER; NONHUMAN; ORAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

4-NITROQUINOLINE-1-OXIDE; ACETYL-COA CARBOXYLASE; ANIMALS; ANTICARCINOGENIC AGENTS; ARECOLINE; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2; FENOFIBRATE; HYPOLIPIDEMIC AGENTS; LIPIDS; MALE; MICE; MICE, INBRED C57BL; MOUTH NEOPLASMS; PPAR ALPHA; RECEPTOR, EPIDERMAL GROWTH FACTOR; TONGUE;

ARECA CATECHU; MUS; NICOTIANA TABACUM;

EID: 79951680010     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.11.002     Document Type: Article

References (27)

1. Nair U., Bartsch H., Nair J. Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: a review of agents and causative mechanisms. Mutagenesis 2004, 19:251-262.
2. Chen Y.J., Chang J.T., Liao C.T., Wang H.M., Yen T.C., Chiu C.C., et al. Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Sci. 2008, 99:1507-1514.
3. Patel B.P., Rawal U.M., Rawal R.M., Shukla S.N., Patel P.S. Tobacco, antioxidant enzymes, oxidative stress, and genetic susceptibility in oral cancer. Am. J. Clin. Oncol. 2008, 31:454-459.
4. Chang Y.C., Hu C.C., Tseng T.H., Tai K.W., Li C.K., Chou M.Y. Synergetic effect of nicotine on arecoline induced cytotoxicity in human buccal mucosa fibroblasts. J. Oral Pathol. Med. 2001, 30:458-464.
5. Manoharan S., Kolanjiappan K., Suresh K., Panjamurthy K. Lipid peroxidation and antioxidants status in patients with oral squamous cell carcinoma. Indian J. Med. Res. 2005, 122:529-534.
6. Chyou P.H., Nomura A.M., Stemmermann G.N., Kato I. Prospective study of serum cholesterol and site-specific cancers. J. Clin. Epidemiol. 1992, 45:287-292.
7. Patel P.S., Shah M.H., Jha F.P., Raval G.N., Rawal R.M., Patel M.M., et al. Alterations in plasma lipid profile patterns in head and neck cancer and oral precancerous conditions. Indian J. Cancer 2004, 41:25-31.
8. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchard J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998, 98:2088-2093.
9. Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 1999, 20:649-688.
10. Fruchart J.C. Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. Am. J. Cardiol. 2001, 88:24-29.
11. Barbier O., Torra I.P., Duguay Y., Blanquart C., Fruchart J.C., Glineur C., et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2002, 22:717-726.
12. Chapman M.J. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003, 171:1-13.
13. Keating G.M., Croom K.F. Fenofibrate: a review of its use in primary dyslipidemia, the metabolic syndrome and type 2 diabetes mellitus. Drug 2007, 67:121-153.
14. Vitale-Cross L., Czerninski R., Amornphimoltham P., Patel V., Molinolo A.A., Gutkind J.S. Chemical carcinogenesis models for evaluating molecular-targeted prevention and treatment of oral cancer. Cancer Prev. Res. (Philadelphia, PA) 2009, 2:419-422.
15. Chang N.W., Pei R.J., Tseng H.C., Yeh K.T., Chan H.C., Lee M.R., et al. Co-treating with arecoline and 4-nitroquinoline 1-oxide to establish a mouse model mimicking oral tumorigenesis. Chem. Biol. Interact. 2010, 183:231-237.
16. Sheu J.J., Hua C.H., Wan L., Lin Y.J., Lai M.T., Tseng H.C., et al. Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res. 2009, 69:2568-2576.
17. Lai C.H., Chang N.W., Lin C.F., Lin C.D., Lin Y.J., Wan L., et al. Proteomics-based identification of haptoglobin as a novel plasma biomarker in oral squamous cell carcinoma. Clin. Chim. Acta 2010, 441:984-991.
18. Moraitis D., Du B., De Lorenzo M.S., Boyle J.O., Weksler B.B., Cohen E.G., et al. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res. 2005, 65:664-670.
19. Suzuki R., Kohno H., Suzui M., Yoshimi N., Tsuda H., Wakabayashi K., et al. An animal model for the rapid induction of tongue neoplasms in human c-Ha-ras proto-oncogene transgenic rats by 4-nitroquinoline 1-oxide: its potential use for preclinical chemoprevention studies. Carcinogenesis 2006, 27:619-630.
20. Farnier M. Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. Vasc. Health Risk Manag. 2008, 4:991-1000.
21. Fazio S., Linton M.F. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr. Atheroscler. Rep. 2004, 6:148-157.
22. Grabacka M., Placha W., Plonka P.M., Pajak S., Urbanska K., Laidler P., et al. Inhibition of melanoma metastases by fenofibrate. Arch. Dermatol. Res. 2004, 296:54-58.
23. Saidi S.A., Holland C.M., Charnock-Jones D.S., Smith S.K. In vitro and in vivo effects of the PPARα agonists fenofibrate and retinoic acid in endometrial cancer. Mol. Cancer 2006, 5:13.
24. Panigrahy D., Kaipainen A., Huang S., Butterfield C.E., Barnés C.M., Fannon M., et al. PPAR alpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc. Natl Acad. Sci. USA 2008, 105:985-990.
25. Tsujii M., DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 1995, 83:493-501.
26. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93:705-716.
27. Cohen E.G., Almahmeed T., Du B., Golijanin D., Boyle J.O., Soslow R.A., et al. Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma. Clin. Cancer Res. 2003, 9:3425-3430.